Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1073354-96-7

Post Buying Request

1073354-96-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1073354-96-7 Usage

Uses

3-Amino-2-chloropyridine-5-boronic acid, pinacol ester

Check Digit Verification of cas no

The CAS Registry Mumber 1073354-96-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,3,3,5 and 4 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1073354-96:
(9*1)+(8*0)+(7*7)+(6*3)+(5*3)+(4*5)+(3*4)+(2*9)+(1*6)=147
147 % 10 = 7
So 1073354-96-7 is a valid CAS Registry Number.

1073354-96-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine

1.2 Other means of identification

Product number -
Other names 3-Amino-2-chloropyridine-5-boronic acid,pinacol ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1073354-96-7 SDS

1073354-96-7Relevant articles and documents

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach

Chen, Chao,Zhu, Hugh,Stauffer, Frédéric,Caravatti, Giorgio,Vollmer, Susanne,Machauer, Rainer,Holzer, Philipp,M?bitz, Henrik,Scheufler, Clemens,Klumpp, Martin,Tiedt, Ralph,Beyer, Kim S.,Calkins, Keith,Guthy, Daniel,Kiffe, Michael,Zhang, Jeff,Gaul, Christoph

, p. 735 - 740 (2016)

Oncogenic MLL fusion proteins aberrantly recruit Dot1L, a histone methyltransferase, to ectopic loci, leading to local hypermethylation of H3K79 and misexpression of HoxA genes driving MLL-rearranged leukemias. Inhibition of the methyltransferase activity of Dot1L in this setting is predicted to reverse aberrant H3K79 methylation, leading to repression of leukemogenic genes and tumor growth inhibition. In the context of our Dot1L drug discovery program, high-throughput screening led to the identification of 2, a weak Dot1L inhibitor with an unprecedented, induced pocket binding mode. A medicinal chemistry campaign, strongly guided by structure-based consideration and ligand-based morphing, enabled the discovery of 12 and 13, potent, selective, and structurally completely novel Dot1L inhibitors.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

-

Page/Page column 165, (2014/06/11)

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Inhibitors of PI3 kinase

-

Page/Page column 37-38, (2009/07/10)

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1073354-96-7